The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Open accessAbstract
Purpose: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods: In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. The primary end point was overall survival. Results: CPX-351 significantly improved median overall survival versus 7+3 (9.56 v 5.95 months; hazard ratio, 0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also significantly higher with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomes were observed across age-groups and AML subtypes. The incidences of nonhematologic adverse events were comparable between arms, despite a longer treatment phase and prolonged time to neutrophil and platelet count recovery with CPX-351. Early mortality rates with CPX-351 and 7+3 were 5.9% and 10.6% (two-sided P = .149) through day 30 and 13.7% and 21.2% (two-sided P = .097) through day 60. Conclusion: CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML. The safety profile of CPX-351 was similar to that of conventional 7+3 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Self-citationJuliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., & Höglund, M. (2009) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 987
Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J. K., Grever, M. R., Appelbaum, F. R., et al. (1999) · PubMed · doi:10.1182/blood.v94.3.1086.415k32_1086_1099 · Cited by 573
An update of current treatments for adult acute myeloid leukemia
Dombret, H., & Gardin, C. (2016) · Blood · doi:10.1182/blood-2015-08-604520 · Cited by 550
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B
Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., et al. (1981) · Blood · doi:10.1182/blood.v58.6.1203.1203 · Cited by 532
Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Granfeldt Østgård, L. S., Medeiros, B. C., Sengeløv, H., Nørgaard, M., Andersen, M. K., Dufva, I. H., Friis, L. S., Kjeldsen, E., Marcher, C. W., Preiss, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0890 · Cited by 451
Self-citationAraki, D., Wood, B. L., Othus, M., Radich, J. P., Halpern, A. B., Zhou, Y., Mielcarek, M., Estey, E. H., Appelbaum, F. R., & Walter, R. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3826 · Cited by 400
Jw, Y., Hj, W., Rr, E., & Jf, H. (1973) · PubMed · Cited by 366
Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., & Mayer, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 356
Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., Komrokji, R., Solomon, S. R., Kolitz, J. E., Cooper, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-540971 · Cited by 339
Self-citationMayer, L. D., Harasym, T. O., Tardi, P. G., Harasym, N. L., Shew, C. R., Johnstone, S. A., Ramsay, E. C., Bally, M. B., & Janoff, A. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0118 · Cited by 331
Feldman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., Allen, S. L., Asatiani, E., Mayer, L. D., Swenson, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5961 · Cited by 310
Self-citationSchoch, C., Kern, W., Schnittger, S., Hiddemann, W., & Haferlach, T. (2004) · Leukemia · doi:10.1038/sj.leu.2403187 · Cited by 284
Hulegårdh, E., Nilsson, C., Lazarevic, V., Garelius, H., Antunovic, P., Rangert Derolf, Å., Möllgård, L., Uggla, B., Wennström, L., Wahlin, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23908 · Cited by 269
Lim, W.-S., Tardi, P. G., Dos Santos, N., Xie, X., Fan, M., Liboiron, B. D., Huang, X., Harasym, T. O., Bermudes, D., & Mayer, L. D. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.01.015 · Cited by 164
Burnett, A. K., Milligan, D. W., Goldstone, A. H., Prentice, A. G., McMullin, M., Dennis, M. W., Sellwood, E., Pallis, M., Russell, N. H., Hills, R. K., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07604.x · Cited by 139
Miesner, M., Haferlach, C., Bacher, U., Weiss, T., Macijewski, K., Kohlmann, A., Klein, H., Dugas, M., Kern, W., Schnittger, S., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279794 · Cited by 129
Lichtman, M. A. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.10.005 · Cited by 125
Feldman, E. J., Kolitz, J. E., Trang, J. M., Liboiron, B. D., Swenson, C. E., Chiarella, M. T., Mayer, L. D., Louie, A. C., & Lancet, J. E. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.07.006 · Cited by 103
Self-citationKim, H. P., Gerhard, B., Harasym, T. O., Mayer, L. D., & Hogge, D. E. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.04.001 · Cited by 88
Self-citationStone, R. M., Mazzola, E., Neuberg, D. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0952 · Cited by 69
Self-citationGordon, M. J., Tardi, P. G., Loriaux, M., Spurgeon, S. E. F., Traer, E. A., Kovacsovics, T. J., Mayer, L. D., & Tyner, J. W. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.12.002 · Cited by 25
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Targeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis, R. M., Wang, R., Davidoff, A., Ma, X., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.005 · Cited by 941
Metadata
- Authors
- Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., Stone, R. M., Bixby, D. L., Kolitz, J. E., Schiller, G. J., Wieduwilt, M. J., Ryan, D. H., Hoering, A., Banerjee, K., Chiarella, M., Louie, A. C., & Medeiros, B. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-09-10
- Volume
- 36
- Issue
- 26
- Pages
- 2684-2692
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2883399820
- Cited by
- 1,025
- References
- 33
- FWCI
- 66.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.